Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.…
Alzheimer's families just lost one of their biggest hopes
Acumen Pharmaceuticals (NASDAQ: ABOS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 60 employees.
The shares were at 0.1865 USD on 20 November 2026, down 91.7% over 52 weeks. Its 52-week range is 0.1601 USD to 3.600 USD: the price is 94.8% below the high and 16.5% above the low.
Its market capitalisation is 13.49M USD.
Acumen Pharmaceuticals reports return on equity of -172.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 52.29M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 18 March 2027.